Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

recent transcribed audio

Report any issue

Recorded24 Nov 2025

Handlerec:19315700

Show notes

Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy

“What did the council decide on item 42?” — answered with the speaker and the moment.